ACADNasdaqPharmaceutical PreparationsFiscal year ends December 31
ACADIA PHARMACEUTICALS INC
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 5, 2026
$19.80+0.68 (+3.56%)
Close on Oct 19, 2026
- Market cap
- $3.42B
- P/E (TTM)
- 9.0
- Dividend yield
- –
Ownership
Institutional holdings as of Jun 30, 2026, from 13F filings
Held by institutions
97.9%
169M of 172M shares
Institutional holders
352
50 new, 35 sold out
Net institutional buying
4M
In Q2 2026
Insider trades, 12 months
0 buys · 24 sales
Net sold $3.40M
Shares held by institutions
Holders of more than 5%
Latest Schedule 13D (active) or 13G (passive) filed by each holder
| Holder | Shares | % of class | Filing | As of |
|---|---|---|---|---|
| State Street Corporation | 9,076,212 | 5.30% | 13G (passive) | Jun 30, 2026 |
| Vanguard Portfolio Management | 8,781,007 | 5.15% | 13G (passive) | Mar 31, 2026 |
| RTW Investments, LP | 8,705,501 | 5.20% | 13G (passive) amendment | Dec 31, 2024 |
| Julian C. Baker | 43,294,373 | 25.40% | 13D (active) amendment | Feb 24, 2026 |
| BlackRock, Inc. | 19,878,746 | 11.90% | 13G (passive) amendment | Jan 31, 2025 |
Top institutional holders
13F holdings as of Jun 30, 2026
| Holder | Shares | % of ACAD | Value | Change | % of portfolio |
|---|---|---|---|---|---|
| Baker Bros. Advisors LP | 42,912,904 | 24.91% | $1.09B | +16,214 | 5.44% |
| BlackRock, Inc. | 22,515,173 | 13.07% | $569.63M | +964,252 | 0.01% |
| State Street Corp | 9,076,212 | 5.27% | $229.63M | +743,441 | 0.01% |
| Vanguard Portfolio Management LLC | 8,838,450 | 5.13% | $223.61M | +166,805 | 0.01% |
| Rtw Investments, LP | 7,144,524 | 4.15% | $180.76M | – | 1.54% |
| Vanguard Capital Management LLC | 5,763,750 | 3.35% | $145.82M | +102,350 | 0.00% |
| Dimensional Fund Advisors LP | 3,694,988 | 2.14% | $93.48M | +539,828 | 0.02% |
| Geode Capital Management, LLC | 3,358,129 | 1.95% | $84.98M | −106,560 | 0.00% |
| Palo Alto Investors LP | 2,864,096 | 1.66% | $72.46M | −8,599 | 10.01% |
| Goldman Sachs Group Inc | 2,580,115 | 1.50% | $65.28M | +1,022,311 | 0.01% |
| Qube Research & Technologies Ltd | 2,446,610 | 1.42% | $61.90M | +1,496,311 | 0.06% |
| Point72 Asset Management, L.P. | 2,433,168 | 1.41% | $61.56M | −144,748 | 0.07% |
| Citadel Advisors LLC | 2,182,177 | 1.27% | $55.21M | +1,559,417 | 0.01% |
| Pictet Asset Management Holding SA | 1,983,198 | 1.15% | $50.15M | −42,846 | 0.05% |
| Arrowstreet Capital, Limited Partnership | 1,969,445 | 1.14% | $49.83M | +399,954 | 0.02% |
| Marshall Wace, Llp | 1,764,838 | 1.02% | $44.65M | +1,688,651 | 0.04% |
| D. E. Shaw & Co., Inc. | 1,697,937 | 0.99% | $42.96M | +968,101 | 0.02% |
| Braidwell LP | 1,646,399 | 0.96% | $41.65M | −824,800 | 1.54% |
| Norges Bank | 1,623,308 | 0.94% | $41.07M | New | 0.00% |
| Frazier Life Sciences Management, L.P. | 1,438,198 | 0.83% | $36.39M | – | 0.79% |
Institutional buying and selling by quarter
Positions opened, added to, reduced and closed by 13F filers
| Quarter | Holders | Shares held | % of shares | New / added | Reduced / closed | Shares bought | Shares sold |
|---|---|---|---|---|---|---|---|
| Q2 2026 | 352 | 169M | 97.9% | 50 / 134 | 112 / 35 | 17M | 13M |
| Q1 2026 | 343 | 165M | 95.8% | 46 / 114 | 129 / 34 | 28M | 14M |
| Q4 2025 | 336 | 166M | 96.6% | 53 / 121 | 118 / 43 | 16M | 17M |
| Q3 2025 | 334 | 168M | 97.5% | 58 / 126 | 106 / 32 | 20M | 23M |
| Q2 2025 | 311 | 171M | 99.3% | 47 / 102 | 122 / 54 | 15M | 17M |
| Q1 2025 | 320 | 173M | 100.0% | 64 / 101 | 102 / 37 | 30M | 19M |
| Q4 2024 | 296 | 163M | 94.8% | 70 / 108 | 75 / 29 | 23M | 17M |
| Q3 2024 | 258 | 157M | 91.2% | 36 / 90 | 81 / 42 | 26M | 19M |
| Q2 2024 | 266 | 162M | 94.1% | 40 / 108 | 81 / 38 | 19M | 23M |
| Q1 2024 | 268 | 166M | 96.3% | 51 / 104 | 74 / 55 | 18M | 14M |
| Q4 2023 | 276 | 162M | 93.9% | 60 / 105 | 70 / 29 | 15M | 9M |
| Q3 2023 | 248 | 156M | 90.7% | 40 / 94 | 72 / 27 | 14M | 16M |
Top mutual fund and ETF holders
Latest monthly portfolio reports (Form N-PORT)
| Fund | Shares | % of ACAD | Value | % of fund | As of |
|---|---|---|---|---|---|
| iShares Core S&P Small-Cap ETF | 7,634,753 | 4.43% | $193.16M | 0.17% | Jun 30, 2026 |
| Vanguard Total Stock Market Index Fund | 4,074,465 | 2.36% | $103.08M | 0.00% | Jun 30, 2026 |
| State Street(R) SPDR(R) S&P(R) Biotech ETF | 3,977,187 | 2.31% | $100.62M | 0.94% | Jun 30, 2026 |
| iShares Russell 2000 ETF | 3,348,997 | 1.94% | $84.73M | 0.10% | Jun 30, 2026 |
| Vanguard Small-Cap Index Fund | 2,949,287 | 1.71% | $74.62M | 0.04% | Jun 30, 2026 |
| Vanguard Small-Cap Growth Index Fund | 1,699,377 | 0.99% | $42.99M | 0.09% | Jun 30, 2026 |
| Vanguard Extended Market Index Fund | 1,457,420 | 0.85% | $36.87M | 0.04% | Jun 30, 2026 |
| Fidelity Small Cap Index Fund | 1,408,238 | 0.82% | $36.43M | 0.11% | Jul 31, 2026 |
| iShares Biotechnology ETF | 1,196,003 | 0.69% | $30.26M | 0.33% | Jun 30, 2026 |
| iShares Russell 2000 Growth ETF | 1,189,901 | 0.69% | $30.10M | 0.20% | Jun 30, 2026 |
| State Street(R) SPDR(R) Portfolio S&P 600(TM) Small Cap ETF | 1,166,003 | 0.68% | $29.50M | 0.17% | Jun 30, 2026 |
| iShares S&P Small-Cap 600 Growth ETF | 1,138,699 | 0.66% | $28.81M | 0.35% | Jun 30, 2026 |
| Artisan International Small-Mid Fund | 823,219 | 0.48% | $20.83M | 0.82% | Jun 30, 2026 |
| Vanguard Tax-Managed Small-Cap Fund | 812,021 | 0.47% | $20.54M | 0.18% | Jun 30, 2026 |
| State Street(R) SPDR(R) S & P 600(TM) Small Cap Growth ETF | 728,230 | 0.42% | $18.42M | 0.35% | Jun 30, 2026 |
Officers, directors and major owners
People who filed Forms 3, 4 or 5 in the last two years
| Name | Role | Shares owned | % of shares | Latest filing |
|---|---|---|---|---|
| Adams Catherine Owen | Chief Executive Officer, Director | 14,803 | 0.01% | Mar 26, 2026 |
| Mark C. Schneyer | EVP, CHIEF FINANCIAL OFFICER | 82,120 | 0.05% | Aug 7, 2026 |
| Elizabeth H.Z. Thompson | EVP, Head of Research & Dev | 19,044 | 0.01% | Jul 31, 2026 |
| James Kihara | PRINCIPAL ACCOUNTING OFFICER | 13,088 | 0.01% | Jun 29, 2026 |
| Jennifer J. Rhodes | EVP, CHIEF LEGAL OFFICER, SEC | 11,280 | 0.01% | Mar 26, 2026 |
| Thomas Garner | EVP, Chief Commercial Officer | – | – | Mar 10, 2026 |
| Brendan Teehan | EVP, COO, HEAD OF COMMERCIAL | 62,105 | 0.04% | Nov 19, 2024 |
| Bros. Advisors (GP) LLC Baker | Director, 10% owner | 3,761,611 | 2.18% | Jun 2, 2026 |
| Brothers Life Sciences LP Baker | Director, 10% owner | 39,487,463 | 22.92% | Jun 2, 2026 |
| Felix Baker | Director, 10% owner | 38,587,857 | 22.40% | Jun 2, 2026 |
| 667, L.P. | Director, 10% owner | 39,132,562 | 22.71% | Jun 2, 2026 |
| Bros. Advisors Lp Baker | Director, 10% owner | 39,452,627 | 22.90% | Jun 2, 2026 |
| Julian Baker | Director, 10% owner | 39,433,853 | 22.89% | Jun 2, 2026 |
| Jonathan Poole | Director | 2,010 | 0.00% | Jun 1, 2026 |
| James M. Daly | Director | 12,148 | 0.01% | Jun 1, 2026 |
| Edmund Harrigan | Director | 43,148 | 0.03% | Jun 1, 2026 |
| Laura Brege | Director | 23,202 | 0.01% | Jun 1, 2026 |
| Elizabeth A. Garofalo | Director | 33,489 | 0.02% | Jun 1, 2026 |
| Adora Ndu | Director | 32,908 | 0.02% | Jun 1, 2026 |
| Daniel B. Soland | Director | 44,041 | 0.03% | Jun 2, 2025 |
Insider trades
Common stock transactions reported on Form 4, newest first
| Insider | Date | Transaction | Shares | Price | Value | Shares after |
|---|---|---|---|---|---|---|
| Mark C. Schneyer EVP, CHIEF FINANCIAL OFFICER | Aug 6, 2026 | Option exercise | +14,292 | $17.84 | $254.97K | 82,120 |
| Mark C. Schneyer EVP, CHIEF FINANCIAL OFFICER | Aug 6, 2026 | Sale(10b5-1 plan) | −9,292 | $29.34 | $272.63K | 67,828 |
| Mark C. Schneyer EVP, CHIEF FINANCIAL OFFICER | Aug 6, 2026 | Sale(10b5-1 plan) | −5,000 | $29.00 | $145.00K | 77,120 |
| Mark C. Schneyer EVP, CHIEF FINANCIAL OFFICER | Aug 5, 2026 | Sale(10b5-1 plan) | −5,849 | $29.00 | $169.62K | 67,828 |
| Mark C. Schneyer EVP, CHIEF FINANCIAL OFFICER | Aug 5, 2026 | Option exercise | +5,849 | $17.84 | $104.35K | 73,677 |
| Elizabeth H.Z. Thompson EVP, Head of Research & Dev | Jul 30, 2026 | Sale(10b5-1 plan) | −16,508 | $26.13 | $431.35K | 19,044 |
| Elizabeth H.Z. Thompson EVP, Head of Research & Dev | Jul 30, 2026 | Sale(10b5-1 plan) | −50 | $26.17 | $1.31K | 18,994 |
| Elizabeth H.Z. Thompson EVP, Head of Research & Dev | Jul 29, 2026 | Option exercise | +32,272 | – | – | 35,552 |
| James Kihara PRINCIPAL ACCOUNTING OFFICER | Jun 26, 2026 | Sale(10b5-1 plan) | −11,421 | $26.08 | $297.86K | 13,088 |
| Brothers Life Sciences LP Baker Director, 10% owner | May 29, 2026 | Award | +18,622 | – | – | 39,384,587 |
| Brothers Life Sciences LP Baker Director, 10% owner | May 29, 2026 | Award | +18,622 | – | – | 3,677,357 |
| Edmund Harrigan Director | May 29, 2026 | Option exercise | +8,107 | – | – | 43,148 |
| Jonathan Poole Director | May 29, 2026 | Option exercise | +2,010 | – | – | 2,010 |
| Adora Ndu Director | May 29, 2026 | Option exercise | +8,107 | – | – | 32,908 |
| Laura Brege Director | May 29, 2026 | Option exercise | +8,107 | – | – | 23,202 |
| Elizabeth A. Garofalo Director | May 29, 2026 | Option exercise | +8,107 | – | – | 33,489 |
| James M. Daly Director | May 29, 2026 | Option exercise | +8,107 | – | – | 12,148 |
| James Kihara PRINCIPAL ACCOUNTING OFFICER | May 26, 2026 | Sale | −5,401 | $21.18 | $114.39K | 24,509 |
| Mark C. Schneyer EVP, CHIEF FINANCIAL OFFICER | May 4, 2026 | Sale(10b5-1 plan) | −3,506 | $21.79 | $76.40K | 66,145 |
| James Kihara PRINCIPAL ACCOUNTING OFFICER | May 4, 2026 | Sale(10b5-1 plan) | −1,332 | $21.79 | $29.02K | 29,129 |
| Mark C. Schneyer EVP, CHIEF FINANCIAL OFFICER | May 1, 2026 | Option exercise | +6,815 | – | – | 69,651 |
| James Kihara PRINCIPAL ACCOUNTING OFFICER | May 1, 2026 | Option exercise | +2,596 | – | – | 30,461 |
| James Kihara PRINCIPAL ACCOUNTING OFFICER | Apr 7, 2026 | Sale(10b5-1 plan) | −1,030 | $22.20 | $22.87K | 27,865 |
| Mark C. Schneyer EVP, CHIEF FINANCIAL OFFICER | Apr 7, 2026 | Sale(10b5-1 plan) | −2,709 | $22.20 | $60.14K | 62,836 |
| James Kihara PRINCIPAL ACCOUNTING OFFICER | Apr 5, 2026 | Option exercise | +2,010 | – | – | 28,895 |
| Mark C. Schneyer EVP, CHIEF FINANCIAL OFFICER | Apr 5, 2026 | Option exercise | +5,276 | – | – | 65,545 |
| Mark C. Schneyer EVP, CHIEF FINANCIAL OFFICER | Mar 26, 2026 | Sale(10b5-1 plan) | −37 | $21.72 | $804 | 60,269 |
| Mark C. Schneyer EVP, CHIEF FINANCIAL OFFICER | Mar 26, 2026 | Sale(10b5-1 plan) | −3,171 | $21.65 | $68.65K | 60,306 |
| James Kihara PRINCIPAL ACCOUNTING OFFICER | Mar 26, 2026 | Sale(10b5-1 plan) | −12 | $21.73 | $261 | 26,885 |
| James Kihara PRINCIPAL ACCOUNTING OFFICER | Mar 26, 2026 | Sale(10b5-1 plan) | −1,097 | $21.65 | $23.75K | 26,897 |
| Mark C. Schneyer EVP, CHIEF FINANCIAL OFFICER | Mar 25, 2026 | Sale(10b5-1 plan) | −4,177 | $21.47 | $89.68K | 57,299 |
| Mark C. Schneyer EVP, CHIEF FINANCIAL OFFICER | Mar 25, 2026 | Option exercise | +6,178 | – | – | 63,477 |
| Elizabeth H.Z. Thompson EVP, Head of Research & Dev | Mar 25, 2026 | Sale(10b5-1 plan) | −3,435 | $21.47 | $73.75K | 3,280 |
| Adams Catherine Owen Chief Executive Officer, Director | Mar 25, 2026 | Sale(10b5-1 plan) | −11,641 | $21.47 | $249.93K | 14,803 |
| Jennifer J. Rhodes EVP, CHIEF LEGAL OFFICER, SEC | Mar 25, 2026 | Sale(10b5-1 plan) | −3,844 | $21.47 | $82.53K | 11,280 |
| James Kihara PRINCIPAL ACCOUNTING OFFICER | Mar 25, 2026 | Option exercise | +2,142 | – | – | 27,994 |
| James Kihara PRINCIPAL ACCOUNTING OFFICER | Mar 25, 2026 | Sale(10b5-1 plan) | −833 | $21.47 | $17.88K | 25,852 |
| Mark C. Schneyer EVP, CHIEF FINANCIAL OFFICER | Mar 24, 2026 | Option exercise | +8,138 | – | – | 61,476 |
| Elizabeth H.Z. Thompson EVP, Head of Research & Dev | Mar 24, 2026 | Option exercise | +6,715 | – | – | 6,715 |
| Adams Catherine Owen Chief Executive Officer, Director | Mar 24, 2026 | Option exercise | +23,509 | – | – | 26,444 |
| Jennifer J. Rhodes EVP, CHIEF LEGAL OFFICER, SEC | Mar 24, 2026 | Option exercise | +7,515 | – | – | 15,124 |
| James Kihara PRINCIPAL ACCOUNTING OFFICER | Mar 24, 2026 | Option exercise | +1,627 | – | – | 26,685 |
| Jennifer J. Rhodes EVP, CHIEF LEGAL OFFICER, SEC | Feb 9, 2026 | Sale(10b5-1 plan) | −6,950 | $23.38 | $162.49K | 7,609 |
| Jennifer J. Rhodes EVP, CHIEF LEGAL OFFICER, SEC | Feb 6, 2026 | Option exercise | +12,944 | – | – | 14,559 |
| James Kihara PRINCIPAL ACCOUNTING OFFICER | Nov 18, 2025 | Sale(10b5-1 plan) | −4,084 | $23.69 | $96.75K | 25,058 |
| Mark C. Schneyer EVP, CHIEF FINANCIAL OFFICER | Nov 18, 2025 | Sale(10b5-1 plan) | −10,262 | $23.69 | $243.11K | 53,338 |
| James Kihara PRINCIPAL ACCOUNTING OFFICER | Nov 17, 2025 | Option exercise | +3,966 | – | – | 25,176 |
| James Kihara PRINCIPAL ACCOUNTING OFFICER | Nov 17, 2025 | Option exercise | +3,966 | – | – | 29,142 |
| Mark C. Schneyer EVP, CHIEF FINANCIAL OFFICER | Nov 17, 2025 | Option exercise | +9,913 | – | – | 63,600 |
| Mark C. Schneyer EVP, CHIEF FINANCIAL OFFICER | Nov 17, 2025 | Option exercise | +9,913 | – | – | 53,687 |
| James M. Daly Director | Nov 10, 2025 | Sale | −30,000 | $22.37 | $671.10K | 4,041 |
| Mark C. Schneyer EVP, CHIEF FINANCIAL OFFICER | Sep 15, 2025 | Sale(10b5-1 plan) | −3,498 | $23.65 | $82.73K | 43,447 |
| Mark C. Schneyer EVP, CHIEF FINANCIAL OFFICER | Sep 12, 2025 | Award | +6,815 | – | – | 46,945 |
| Elizabeth A. Garofalo Director | Sep 2, 2025 | Sale | −1,600 | $25.98 | $41.57K | 25,382 |
| Mark C. Schneyer EVP, CHIEF FINANCIAL OFFICER | Aug 18, 2025 | Sale(10b5-1 plan) | −22,000 | $25.18 | $553.96K | 40,130 |
| Laura Brege Director | Jun 4, 2025 | Sale | −14,446 | $21.78 | $314.63K | 15,095 |
| Edmund Harrigan Director | May 29, 2025 | Option exercise | +9,387 | – | – | 35,041 |
| Laura Brege Director | May 29, 2025 | Option exercise | +9,387 | – | – | 29,541 |
| Daniel B. Soland Director | May 29, 2025 | Option exercise | +9,387 | – | – | 44,041 |
| Elizabeth A. Garofalo Director | May 29, 2025 | Option exercise | +9,387 | – | – | 26,982 |
Awards, option exercises, tax withholding and gifts are shown alongside open-market buys and sales. Each name links to the filing on SEC EDGAR.
Planned insider sales
Notices of proposed sale filed on Form 144 before shares are sold
| Seller | Filed | Shares | Market value | Planned sale | Acquired through |
|---|---|---|---|---|---|
| Mark C. Schneyer Officer | Aug 5, 2026 | 5,849 | $158.80K | Aug 5, 2026 | Stock Option Exercise |
| James Kihara Officer | Jun 26, 2026 | 11,421 | $297.00K | Jun 26, 2026 | Compensation |
| K. Kihara James Officer | May 26, 2026 | 5,401 | $114.39K | May 26, 2026 | Performance Shares |
| M. Daly James Director | Nov 10, 2025 | 30,000 | $670.98K | Nov 10, 2025 | Restricted Stock |
| Mark C. Schneyer Officer | Aug 18, 2025 | 22,000 | $557.26K | Aug 18, 2025 | Compensation |
| Brege Laura Director | Jun 4, 2025 | 14,446 | $314.64K | Jun 4, 2025 | Restricted Stock |
| Mark C. Schneyer Officer | May 16, 2025 | 2,000 | $35.20K | May 16, 2025 | Compensation |
| James Kihara Officer | May 16, 2025 | 4,000 | $70.40K | May 16, 2025 | Compensation |
| Elizabeth A. Garofalo Director | Mar 6, 2025 | 4,919 | $89.67K | Mar 5, 2025 | RESTRICTED STOCK |
| James Kihara Officer | Dec 15, 2023 | 2,000 | $56.12K | Dec 15, 2023 | Restricted Stock Units |
| James Kihara Officer | Sep 15, 2023 | 2,000 | $51.70K | Sep 15, 2023 | Vested RSU shares |
| Mark C. Schneyer Officer | Aug 21, 2023 | 10,000 | $293.30K | Aug 21, 2023 | Vested RSU Shares |
| Stephen Davis Officer, Director | Jul 14, 2023 | 100,000 | $2.58M | Jul 14, 2023 | Stock Option Exercise |
| Stephen Davis Officer, Director | Jul 13, 2023 | 71,602 | $1.77M | Jul 11, 2023 | Vested RSU shares |
| James Kihara Officer | Jun 15, 2023 | 2,000 | $48.28K | Jun 15, 2023 | Vested RSU shares |